| First Author | Durfee C | Year | 2023 |
| Journal | Cell Rep Med | Volume | 4 |
| Issue | 10 | Pages | 101211 |
| PubMed ID | 37797615 | Mgi Jnum | J:341577 |
| Mgi Id | MGI:7541236 | Doi | 10.1016/j.xcrm.2023.101211 |
| Citation | Durfee C, et al. (2023) Human APOBEC3B promotes tumor development in vivo including signature mutations and metastases. Cell Rep Med 4(10):101211 |
| abstractText | The antiviral DNA cytosine deaminase APOBEC3B has been implicated as a source of mutation in many cancers. However, despite years of work, a causal relationship has yet to be established in vivo. Here, we report a murine model that expresses tumor-like levels of human APOBEC3B. Animals expressing full-body APOBEC3B appear to develop normally. However, adult males manifest infertility, and older animals of both sexes show accelerated rates of carcinogenesis, visual and molecular tumor heterogeneity, and metastasis. Both primary and metastatic tumors exhibit increased frequencies of C-to-T mutations in TC dinucleotide motifs consistent with the established biochemical activity of APOBEC3B. Enrichment for APOBEC3B-attributable single base substitution mutations also associates with elevated levels of insertion-deletion mutations and structural variations. APOBEC3B catalytic activity is required for all of these phenotypes. Together, these studies provide a cause-and-effect demonstration that human APOBEC3B is capable of driving both tumor initiation and evolution in vivo. |
